Insights

Diversified Product Portfolio Mallinckrodt offers a broad range of specialty pharmaceutical products, including branded medicines, generic drugs, active pharmaceutical ingredients, and medical imaging agents, presenting multiple upsell and cross-sell opportunities across therapeutic areas such as autoimmune disorders, neurology, and pulmonology.

Innovative Launches The recent launch of Acthar Gel in self-injectable form for autoimmune conditions demonstrates ongoing product innovation that can be leveraged to introduce complementary devices, technology solutions, or supportive services aimed at healthcare providers and patients.

Focus on Regulatory Expertise Mallinckrodt's specialization in managing highly regulated raw materials and complex chemistry positions it as a potential partner for technology providers seeking to optimize pharmaceutical manufacturing, quality assurance, or regulatory compliance solutions.

Financial Recovery Opportunities Despite recent bankruptcy proceedings, Mallinckrodt has secured significant funding and achieved legal victories, indicating ongoing restructuring efforts; this creates an opportunity to engage in partnership discussions related to supply chain, asset recovery, or new product development initiatives.

Recent Strategic Moves The sale of assets to Yaqrit Limited and leadership changes reflect strategic shifts; business development teams could explore collaboration on alternative formulations, licensing opportunities, or expansion into emerging markets based on these organizational changes.

Similar companies to Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.

Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. Tech Stack

Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. uses 8 technology products and services including LinkedIn Ads, Qlik Sense, TeamCity, and more. Explore Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s tech stack below.

  • LinkedIn Ads
    Advertising
  • Qlik Sense
    Business Intelligence
  • TeamCity
    Continuous Integration
  • Twemoji
    Font Scripts
  • COBIT Framework
    Governance, Risk And Compliance
  • Akamai mPulse
    Real User Monitoring
  • Google
    Search Engines
  • Google Search Console
    Web Analytics

Media & News

Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s Email Address Formats

Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. uses at least 3 format(s):
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. Email FormatsExamplePercentage
First.Last@mallinckrodt.comJohn.Doe@mallinckrodt.com
94%
FLast@mallinckrodt.comJDoe@mallinckrodt.com
2%
Last.First@mallinckrodt.comDoe.John@mallinckrodt.com
2%
FirstLast@mallinckrodt.comJohnDoe@mallinckrodt.com
2%
First.Last@ikaria.comJohn.Doe@ikaria.com
89%
F.Last@ikaria.comJ.Doe@ikaria.com
6%
First@ikaria.comJohn@ikaria.com
3%
Last@ikaria.comDoe@ikaria.com
2%
First.Last@mnk.comJohn.Doe@mnk.com
100%

Frequently Asked Questions

Where is Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s main headquarters is located at 53 Frontage Road po Box 9001 Third Floor Hampton, New Jersey United States. The company has employees across 5 continents, including North AmericaEuropeOceania.

What is Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s official website is mallinckrodt.com and has social profiles on LinkedIn.

What is Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s NAICS code?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. have currently?

Minus sign iconPlus sign icon
As of June 2026, Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. has approximately 91 employees across 5 continents, including North AmericaEuropeOceania. Key team members include Chief Executive Officer: A. T.Chief Executive Officer And Directeur General: D. T.Chief Executive Officer: L. C.. Explore Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s employee directory with LeadIQ.

What industry does Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. belong to?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. use?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s tech stack includes LinkedIn AdsQlik SenseTeamCityTwemojiCOBIT FrameworkAkamai mPulseGoogleGoogle Search Console.

What is Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s email format?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s email format typically follows the pattern of First.Last@mallinckrodt.com. Find more Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. email formats with LeadIQ.

When was Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. founded?

Minus sign iconPlus sign icon
Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc. was founded in 2007.

Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.

Pharmaceutical ManufacturingNew Jersey, United States51-200 Employees

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mission: Managing Complexity. Improving Lives.

Values: Quality, Integrity, Service

Principal Executive Office:
Mallinckrodt plc
Damastown Industrial Estate
Mulhuddart, Dublin 15
Ireland 

U.S. Headquarters:
675 McDonnell Blvd.
St. Louis, MO 63042
USA 

Website: www.mallinckrodt.com
Stock Ticker: MNK
Corporate Blog: http://blog.mallinckrodt.com/ 
Careers Website: www.mallinckrodt.com/careers 
Investor Relations: http://www.mallinckrodt.com/investors

Section iconCompany Overview

Headquarters
53 Frontage Road po Box 9001 Third Floor Hampton, New Jersey United States
Phone number
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2007
Employees
51-200

Section iconFunding & Financials

  • $50M$100M

    Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Mallinckrodt Pharmaceuticals, Formerly IKARIA, Inc.'s revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

ยฉ LeadIQ, Inc. All rights reserved.